- Home
- DEA vs TLRY Comparison
DEA vs TLRY Comparison
Compare DEA & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- TLRY
- Stock Information
- Founded
- DEA 2011
- TLRY N/A
- Country
- DEA United States
- TLRY Canada
- Employees
- DEA N/A
- TLRY N/A
- Industry
- DEA Real Estate Investment Trusts
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- DEA Real Estate
- TLRY Health Care
- Exchange
- DEA Nasdaq
- TLRY Nasdaq
- Market Cap
- DEA 1.2B
- TLRY 1.5B
- IPO Year
- DEA 2015
- TLRY 2018
- Fundamental
- Price
- DEA $11.17
- TLRY $1.26
- Analyst Decision
- DEA Buy
- TLRY Hold
- Analyst Count
- DEA 2
- TLRY 3
- Target Price
- DEA $14.00
- TLRY $1.88
- AVG Volume (30 Days)
- DEA 1.6M
- TLRY 29.6M
- Earning Date
- DEA 11-05-2024
- TLRY 01-09-2025
- Dividend Yield
- DEA 9.49%
- TLRY N/A
- EPS Growth
- DEA N/A
- TLRY N/A
- EPS
- DEA 0.17
- TLRY N/A
- Revenue
- DEA $302,121,000.00
- TLRY $812,037,000.00
- Revenue This Year
- DEA N/A
- TLRY $17.01
- Revenue Next Year
- DEA $9.68
- TLRY $5.96
- P/E Ratio
- DEA $65.49
- TLRY N/A
- Revenue Growth
- DEA 2.98
- TLRY 24.76
- 52 Week Low
- DEA $10.86
- TLRY $1.14
- 52 Week High
- DEA $14.53
- TLRY $2.97
- Technical
- Relative Strength Index (RSI)
- DEA 28.47
- TLRY 35.01
- Support Level
- DEA $11.61
- TLRY $1.15
- Resistance Level
- DEA $11.95
- TLRY $1.38
- Average True Range (ATR)
- DEA 0.28
- TLRY 0.07
- MACD
- DEA -0.04
- TLRY -0.00
- Stochastic Oscillator
- DEA 23.26
- TLRY 16.67
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.